Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

Table 3 Univariate and multivariate analysis for the factors influencing survival rate

Factors	Univariate (P value)	Multivariate (P value)	Exp(B)	95%CI
Cirrhosis of the liver
Absent/Present	0.003	0.083	5.114	0.806-32.436
Pathological Stage
I/II/III/IV	0.013	0.012	0.485	0.276-0.851
TACE Sessions
≤ 2/> 2	0.001	0.001	1.964	1.311-2.942
BCLC Stage
A/B/C	0.005	0.061	0.183	0.031-1.078
Number of Tumor
Single/Multiple	0.017	0.460	1.651	0.437-6.235
CLIP Score
≤ 2/> 2	0.013	0.982	0.992	0.496-1.985
Chemotherapy agent
CPT-11/GEM/Doxorubicin	0.004	0.019	0.407	0.192-0.863
ALB (g/L)
≤ 40/> 40	0.033	0.030	0.834	0.709-0.982

TACE: Transarterial chemoembolization; BCLC: Barcelona Clinic Liver Cancer Group; CLIP: Cancer of the Liver Italian Program; GEM: Gemcitabine; CLIP: Cancer Liver Italian Program; ALB: Albumin; CPT-11: Chemotherapeutic agent irinotecan; GEM: Gemcitabine.